Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dexibuprofen→

Dexibuprofen Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
51146-56-6
Molecular formula
C13H18O2
Molecular weight
206.28 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)pharmacologically active S(+)-enantiomer of ibuprofen
Mechanism of action
A non-selective cyclo-oxygenase inhibitor that reduces prostaglandin synthesis, producing analgesic, anti-inflammatory and antipyretic effects; it also inhibits platelet aggregation.
Indications / reported uses
  • Symptomatic treatment of pain and inflammation in osteoarthritis
  • Primary dysmenorrhoea
  • Mild-to-moderate pain, including musculoskeletal pain, headache and toothache
  • Short-term symptomatic treatment of rheumatoid arthritis when disease-modifying therapy is not being considered; the cited UK SmPC includes adults and children/adolescents from 8 years

Sources: UK SmPC — Dexibuprofen 200 mg tablets (updated 6 Jun 2026) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dexibuprofen Environmental Risk Assessment (ERA) (the Dexibuprofen ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.